# BioLineRx Ltd.: financial statements, quarterly

BLRX · Nasdaq · CIK 1498403 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/blrx.md) · [Financials](/companies/blrx/financials.md) · [Filings](/companies/blrx/filings.md) · [Insiders](/companies/blrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/blrx/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2014-12-31) | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.8](/filings/0001178913-18-000765.md) | [5.5](/filings/0001178913-19-000965.md) | [2.5](/filings/0001178913-20-000790.md) | [5.1](/filings/0001178913-21-000741.md) | [3.4](/filings/0001178913-22-001134.md) | [5.3](/filings/0001178913-23-001091.md) | [16.8](/filings/0001178913-24-001095.md) | [13.0](/filings/0001178913-25-001123.md) | [10.6](/filings/0001178913-26-001581.md) | [4.3](/filings/0001178913-26-001581.md) | [10.4](/filings/0001178913-26-001581.md) | [3.3](/filings/0001178913-26-001581.md) |
| Current assets | $m | not reported | not reported | [36.1](/filings/0001178913-18-000765.md) | [50.4](/filings/0001178913-19-000965.md) | [32.0](/filings/0001178913-20-000790.md) | [28.2](/filings/0001178913-21-000741.md) | [22.9](/filings/0001178913-22-001134.md) | [57.4](/filings/0001178913-23-001091.md) | [52.0](/filings/0001178913-24-001095.md) | [47.2](/filings/0001178913-25-001123.md) | [27.1](/filings/0001178913-26-001581.md) | [23.7](/filings/0001178913-26-001581.md) |
| Total assets | $m | not reported | not reported | [38.9](/filings/0001178913-18-000765.md) | [61.0](/filings/0001178913-19-000965.md) | [56.2](/filings/0001178913-20-000790.md) | [53.6](/filings/0001178913-21-000741.md) | [47.3](/filings/0001178913-22-001134.md) | [81.4](/filings/0001178913-23-001091.md) | [76.4](/filings/0001178913-24-001095.md) | [63.9](/filings/0001178913-25-001123.md) | [38.9](/filings/0001178913-26-001581.md) | [40.9](/filings/0001178913-26-001581.md) |
| Current liabilities | $m | not reported | not reported | [3.7](/filings/0001178913-18-000765.md) | [6.7](/filings/0001178913-19-000965.md) | [6.8](/filings/0001178913-20-000790.md) | [12.0](/filings/0001178913-21-000741.md) | [10.6](/filings/0001178913-22-001134.md) | [9.7](/filings/0001178913-23-001091.md) | [10.7](/filings/0001178913-24-001095.md) | [42.8](/filings/0001178913-25-001123.md) | [15.4](/filings/0001178913-26-001581.md) | [12.1](/filings/0001178913-26-001581.md) |
| Total liabilities | $m | not reported | not reported | [3.9](/filings/0001178913-18-000765.md) | [8.1](/filings/0001178913-19-000965.md) | [14.9](/filings/0001178913-20-000790.md) | [20.2](/filings/0001178913-21-000741.md) | [25.3](/filings/0001178913-22-001134.md) | [13.3](/filings/0001178913-23-001091.md) | [25.5](/filings/0001178913-24-001095.md) | [50.7](/filings/0001178913-25-001123.md) | [25.4](/filings/0001178913-26-001581.md) | [17.6](/filings/0001178913-26-001581.md) |
| Shareholders' equity | $m | [31.8](/filings/0001178913-18-000765.md) | [47.6](/filings/0001178913-19-000965.md) | [35.0](/filings/0001178913-20-000790.md) | [52.9](/filings/0001178913-21-000741.md) | [41.3](/filings/0001178913-22-001134.md) | [33.4](/filings/0001178913-23-001091.md) | [22.0](/filings/0001178913-24-001095.md) | [68.1](/filings/0001178913-25-001123.md) | [50.8](/filings/0001178913-26-001581.md) | [13.2](/filings/0001178913-26-001581.md) | [13.5](/filings/0001178913-26-001581.md) | [18.2](/filings/0001178913-26-001581.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 2,610,814,390 at 2026-03-08, from the cover of the [20-F/A filed 2026-03-27](/filings/0001178913-26-001807.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.